|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Overall, the results presented here suggest that <i>miR-629-5p</i> functions as a tumor promoter by improving proliferation and migration and repressing apoptosis and 5-FU sensitivity in colorectal cancer progression by directly down-regulating CXXC4.
|
30042169 |
2018 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
We previously found that CXXC finger protein 4 (CXXC4) was a novel tumor suppressor in gastric cancer.
|
29262584 |
2017 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
CXXC4 is a novel potential tumor suppressor directly regulated by EZH2, and its expression is a significant prognosis factor for patients with early stages of gastric cancer.
|
23949225 |
2013 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
CXXC4 mRNA levels in tumor samples were significantly lower in patients with metastases compared with those without (P=0.0016).
|
18931698 |
2009 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Together, these findings indicate that BMI1-mediated IDAX epigenetic suppression is crucial for enhancement of colon carcinogenesis, suggesting that BMI1∖IDAX axis as a potential novel diagnostic and therapeutic target of colon cancer.
|
29337063 |
2018 |
|
Malignant neoplasm of stomach
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
CXXC4 activates apoptosis through up-regulating GDF15 in gastric cancer.
|
29262584 |
2017 |
|
Stomach Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
CXXC4 activates apoptosis through up-regulating GDF15 in gastric cancer.
|
29262584 |
2017 |
|
Malignant neoplasm of stomach
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
CXXC4 is a novel potential tumor suppressor directly regulated by EZH2, and its expression is a significant prognosis factor for patients with early stages of gastric cancer.
|
23949225 |
2013 |
|
Carcinogenesis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
In summary, EZH2 promotes the activation of wnt signaling in gastric carcinogenesis through the downregulation of CXXC4 expression.
|
23949225 |
2013 |
|
Stomach Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
CXXC4 is a novel potential tumor suppressor directly regulated by EZH2, and its expression is a significant prognosis factor for patients with early stages of gastric cancer.
|
23949225 |
2013 |
|
Malignant tumor of colon
|
0.010 |
Biomarker
|
disease |
BEFREE |
Together, these findings indicate that BMI1-mediated IDAX epigenetic suppression is crucial for enhancement of colon carcinogenesis, suggesting that BMI1∖IDAX axis as a potential novel diagnostic and therapeutic target of colon cancer.
|
29337063 |
2018 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
<i>MiR-629-5p</i> promotes colorectal cancer progression through targetting CXXC finger protein 4.
|
30042169 |
2018 |
|
Colon Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Together, these findings indicate that BMI1-mediated IDAX epigenetic suppression is crucial for enhancement of colon carcinogenesis, suggesting that BMI1∖IDAX axis as a potential novel diagnostic and therapeutic target of colon cancer.
|
29337063 |
2018 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
Biomarker
|
disease |
BEFREE |
<i>MiR-629-5p</i> promotes colorectal cancer progression through targetting CXXC finger protein 4.
|
30042169 |
2018 |
|
Childhood Myelodysplastic Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CXXC4 mRNA levels are associated with clinicopathological parameters and survival of myelodysplastic syndrome patients.
|
25085016 |
2014 |
|
MYELODYSPLASTIC SYNDROME
|
0.010 |
AlteredExpression
|
group |
BEFREE |
This study demonstrated that the age of patients and levels of CXXC4 mRNA, hemoglobin, and marrow blast associated with survival of MDS patients.
|
25085016 |
2014 |
|
Adult Myelodysplastic Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CXXC4 mRNA levels are associated with clinicopathological parameters and survival of myelodysplastic syndrome patients.
|
25085016 |
2014 |
|
Hepatoblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CITED1 mRNA expression correlates with expression of CXXC4 and KREMEN1 in clinical hepatoblastoma specimens.
|
23308048 |
2012 |
|
Renal Cell Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We identified a CXXC4 homozygous deletion at 4q24 in an aggressive renal cell carcinoma (RCC) using single-nucleotide polymorphism (SNP) arrays.
|
18931698 |
2009 |
|
Neoplasm Metastasis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
CXXC4 mRNA levels in tumor samples were significantly lower in patients with metastases compared with those without (P=0.0016).
|
18931698 |
2009 |
|
Tumor Progression
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
These data suggest that CXXC4 plays a critical role in tumor progression of RCC through Wnt signaling.
|
18931698 |
2009 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We identified a CXXC4 homozygous deletion at 4q24 in an aggressive renal cell carcinoma (RCC) using single-nucleotide polymorphism (SNP) arrays.
|
18931698 |
2009 |
|
Secondary Neoplasm
|
0.010 |
AlteredExpression
|
group |
BEFREE |
CXXC4 mRNA levels in tumor samples were significantly lower in patients with metastases compared with those without (P=0.0016).
|
18931698 |
2009 |
|
Liver carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, some genes were involved with signaling pathways such as Ras/MAPK (MAPKAP1), Src-dependent pathways (CSK), hedgehog signaling pathway (HHIP), while Wnt signaling pathway may not be dominant in woodchuck HCC as shown by the downregulation of beta-catenin (TNNB1) and the upregulation of CXXC4 and CSNK2B.
|
17143510 |
2007 |